From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. 

ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.

Biotechnology

Life Sciences

Therapeutics

Lauren Hudacik

Ana Daniels

Nicolas Salavin

Michèle Ries

Prabha Chandrasekaran

The Scientific Research and Development team at ABL Europe focuses on advancing the development and optimization of GMP viral vector manufacturing processes. This multidisciplinary team employs cutting-edge scientific methodologies to enhance production efficiency, ensure regulatory compliance, and support the successful transition of clients' immunotherapy projects from development to clinical application. By integrating process development and analytical expertise, the team aims to deliver innovative solutions that align with industry standards and client needs.

Scientific Research and Development

Quality Assurance and Control

Production and Manufacturing

Scientific Research and Development

About

Team members

Other teams at ABL

Quality Assurance and Control

Production and Manufacturing